Octapharma is committed to improving awareness of bleeding disorders to help patients like Andrew.

Remaining strong, resilient and agile

The COVID-19 pandemic affected every part of our business, including our patients. Our employees rose to the challenge.

Read the annual report

News & Stories

Final data from the NuProtect study published on the immunogenicity of Nuwiq® in previously untreated patients with severe haemophilia A

Octapharma announced today that the final results from the NuProtect study on the immunogenicity of Nuwiq® in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis.

Octapharma online lectures

03.02.2021

EAHAD 2021

European Association for Haemophilia and Allied Disorders (EAHAD)

28.11.2020

Euroanaesthesia 2020

Euroanaesthesia presents innovations in anaesthesia and other forms of critical care.

14.10.2020

ESID 2020 online meeting

Watch our symposium on demand to learn about the potential use of immunoglobulin in fighting COVID-19.

Check all our virtual events

Patient Engagement

Octapharma takes an active role in our community

We sponsor and support organisations worldwide.

Learn how we engage with patients

Careers and Jobs

Explore a new world of opportunities

Our global presence offers you a great opportunity to gain international experience. Every employee contributes to the ongoing success of the company.

Working with Octapharma

Remaining strong, resilient and agile

Check out our latest stories

Remaining strong, resilient and agile

Delivering strong performance in 2020

Committed to the fight against COVID-19

Final data from the NuProtect study published on the immunogenicity of Nuwiq® in previously untreated patients with severe haemophilia A

Octapharma online lectures

EAHAD 2021

Euroanaesthesia 2020

ESID 2020 online meeting

Octapharma takes an active role in our community

Explore a new world of opportunities

About us

Plasma

Products

Careers

Engagement

News